

A₁

13. (Amended) A protein obtained by the expression of the DNA of [any one of the claims] claim 8[-12] by genetic engineering technique.

16. (Amended) A process for producing a protein by genetic engineering technique using the DNA of [any one of the claims] claim 8[-12].

17. (Amended) A screening method for a substance which controls expression of the protein encoded by the DNA of [any one of the claims] claim 8[-12].

A₂

18. (Amended) A screening method for a substance which specifically binds to the protein encoded by the DNA of [any one of the claims] claim 8[-12] and inhibits or modulates its biological activity.

19. (Amended) A screening method for a substance which specifically binds to the protein encoded by the DNA of [any one of the claims] claim 8[-12] and transmits the biological activity of this protein through the binding.

20. (Amended) A pharmaceutical composition comprising the substance obtained by the screening method described in [claims] claim 17[-19].

A₃

24. (Amended) The DNA of [any one of the claims] claim 21[-23], which encodes a protein specifically binding to Osteoclastogenesis Inhibitory Factor, OCIF, and exhibiting the activity of suppressing its biological activity.

25. (Amended) A DNA of [any one of the claims] claim 21[-24] which has a nucleotide sequence of Sequence ID No. 2 in the Sequence Table.

26. (Amended) A DNA which hybridizes the DNA of [any one of claims] claim 21[-25] under relatively mild conditions.
27. (Amended) A DNA having 70% or more homology to the DNA of [any one of claims] claim 21[-26].
28. (Amended) A protein including a polypeptide which is obtained by expression of the DNA of [any one of the claims] claim 21[-27] by genetic engineering technique.
-
30. (Amended) A protein of ~~claim~~ 28 [or 29] including the amino acid sequence of Sequence ID No. 1 in the Sequence Table, or a fragment, analogue, or variant of the protein.
31. (Amended) A process for producing a protein by genetic engineering technique using the DNA of [any one of the claims] claim 21[-27].
32. (Amended) A screening method for a substance which controls expression of the protein encoded by the DNA of [any one of the claims] claim 21[-27].
33. (Amended) A screening method for a substance which specifically binds to the protein encoded by DNA of [any one of the claims] claim 21[-27] and inhibits or modulates its biological activity.
34. (Amended) A screening method for a substance which specifically binds to a protein encoded by the DNA of [any one of claims] claim 21[-27] and transmits the biological activity of this protein through the binding.

35. (Amended) A pharmaceutical composition comprising the substance obtained by the screening method of [any one of claims] claim 32[-34].

38. (Amended) A DNA of [any one of claims] claim 36[-37] which has a nucleotide sequence of Sequence ID No. 12 in the Sequence Table.

39. (Amended) A DNA which hybridizes to the DNA of [any one of claims] claim 36[-38] under relatively mild conditions.

40. (Amended) A DNA having 70% or more homology to the DNA of [any one of claims] claim 36[-39].

41. (Amended) A protein including a polypeptide which is obtained by expression of the DNA of [any one of the claims] claim 36[-40] by genetic engineering technique.

43. (Amended) A protein of claim 41 [or 42] including the amino acid sequence of Sequence ID No. 11 in the Sequence Table, or a fragment, analogue, or variant of the protein.

44. (Amended) A process for producing a protein by a genetic engineering technique using the DNA of [any one of the claims] claim 36[-40].

45. (Amended) A screening method for a substance which controls expression of the protein encoded by the DNA of [any one of the claims] claim 36[-40].

46. (Amended) A screening method for a substance which specifically binds to the protein encoded by the DNA of [any one of claims] claim 36[-40] and inhibits or modulates its biological activity.
47. (Amended) A screening method for a substance which specifically binds to the protein encoded by the DNA of [any one of claims] claim 36[-40] and transmits the biological activity of this protein through the binding.
48. (Amended) A pharmaceutical composition comprising the substance obtained by the screening method [any one of claims] claim 45[-47].
57. (Amended) A hybridoma which produces the monoclonal antibody of [any one of claims] claim 53[-55].
60. (Amended) A method for measuring OBM, comprising using the antibody of [any one of the claims] claim 49[-55].
61. (Amended) A method for measuring sOBM, comprising using the antibody of [any one of claims] claim 49[-55].
62. (Amended) A method for measuring OBM or sOBM, comprising using the antibody of [any one of claims] claim 49[-55] as an solid phase antibody or an enzyme-labeled antibody.
63. (Amended) A pharmaceutical composition containing the antibody of [any one of claims] claim 49[-55] as an active component.